Firm Pulls World’s First Gene Therapy Treatment: No One Wants It – NBCNews.com
NBCNews.com |
Firm Pulls World’s First Gene Therapy Treatment: No One Wants It
NBCNews.com The biotech company behind the Western world’s first gene therapy and the most expensive prescription medicine in history is giving up on the product because of lack of demand. Only one patient has been treated commercially since the $1 million … UniQure to Yank Pioneering Gene Therapy From Market in EuropeXconomy Goodbye Glybera! The World’s First Gene Therapy will be WithdrawnLabiotech.eu (blog) UniQure Says It Will Not Pursue EC Marketing Renewal for Glybera Gene TherapyGenetic Engineering & Biotechnology News (blog) Seeking Alpha –FiercePharma –pharmaphorum all 11 news articles » |
|
Vericel to Present at the 5th Annual Cell & Gene Therapy Investor Day
Nasdaq CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick … Homology Medicines to Present at the Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor DayPR Newswire (press release) |
Immuno-Oncology News |
Ignyta’s RXDX-106 Works with Immune Checkpoint Inhibitors to Kill Tumors, Study Shows
Immuno-Oncology News Ignyta’s RXDX-106 can restore the body’s immune-system response against several types of tumors and work with immune checkpoint inhibitors to kill tumor cells, according to a company presentation at the American Association for Cancer Research annual … |
|
NYU Langone Research Leads to Accelerated Approval of Bladder Cancer Immunotherapy Drug
Newswise (press release) Clinical trial research led by Arjun V. Balar, MD, of NYU Langone’s Perlmutter Cancer Center, helped pave the way for the recent FDA approval of the immunotherapy drug atezolizumab as a first-line treatment for advanced bladder cancer. |